» Articles » PMID: 10412892

Formulation of Controlled Release Microspheres Containing Nicardipine: the Role of Pharmacokinetic Modeling and Computer Simulation

Overview
Date 1999 Jul 21
PMID 10412892
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Nicardipine is an antihypertensive drug of the dihydropyridine series. It has high solubility in an acidic and low solubility in an alkaline medium. It is rapidly absorbed, extensively presystemically metabolized and excreted in the urine and faeces, mainly as inactive metabolites. Since the duration of its action can be extended by prolonging the absorption interval, the design of controlled release formulation is reasonable. The aim of the present study was to prepare microspheres which would release nicardipine at a decreased rate in gastric and increased rate in intestinal juice during a 12 h interval. Pharmacokinetic modeling based on compartment analysis and supported by analog computer and digital simulation technique showed that the target steady state peak plasma concentrations of 32 microg/l and trough plasma concentration of 7 microg/l would be maintained if nicardipine were incorporated in a formulation releasing the drug as follows: 25% after 1 h, 40% after 2 h, 65% after 4 h, 80% after 6 h, 90% after 8 h and 100% by 12 h. Microspheres have been prepared from hydroxypropylmethylcellulose phthalate polymer using the solvent evaporation method. Drug content, scanning electron micrographs, particle size distribution and dissolution profile were determined. In vitro nicardipine release was described by a biphasic square root of time kinetics and was in accordance with the above values relating to the dissolution. Furthermore, a composed first-pass pharmacokinetic model with derived release function as an input was developed to predict nicardipine plasma concentrations after single- and 12 h multiple-dosage-regimen scheme administration of controlled release microspheres.

Citing Articles

Pathways of paracetamol absorption from layered excipient suppositories: artificial intelligence approach.

Belic A, Grabnar I, Karba R, Mrhar A Eur J Drug Metab Pharmacokinet. 2003; 28(1):31-40.

PMID: 14503662 DOI: 10.1007/BF03190864.

References
1.
Celentano A, Galderisi M, Tammaro P, Mureddu G, Garofalo M, de Divitiis O . Effects on casual and 24-h ambulatory blood pressure of slow-release nicardipine and chlorthalidone in arterial essential hypertension: double-blind, crossover study. Int J Clin Pharmacol Ther Toxicol. 1990; 28(5):190-6. View

2.
Graham D, Dow R, Hall D, Alexander O, Mroszczak E, Freedman D . The metabolism and pharmacokinetics of nicardipine hydrochloride in man. Br J Clin Pharmacol. 1985; 20 Suppl 1:23S-28S. PMC: 1400776. DOI: 10.1111/j.1365-2125.1985.tb05141.x. View

3.
Thuillez C, Gueret M, DUHAZE P, Lhoste F, Kiechel J, Giudicelli J . Nicardipine: pharmacokinetics and effects on carotid and brachial blood flows in normal volunteers. Br J Clin Pharmacol. 1984; 18(6):837-47. PMC: 1463674. DOI: 10.1111/j.1365-2125.1984.tb02553.x. View

4.
Sumimoto T, Hiwada K, Ochi T, Matsubara W, Joh T, Imamura Y . Effects of long-term treatment with sustained-release nicardipine on left ventricular hypertrophy and function in patients with essential hypertension. J Clin Pharmacol. 1994; 34(3):266-9. DOI: 10.1002/j.1552-4604.1994.tb03997.x. View

5.
Sorkin E, Clissold S . Nicardipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in the treatment of angina pectoris, hypertension and related cardiovascular disorders. Drugs. 1987; 33(4):296-345. DOI: 10.2165/00003495-198733040-00002. View